Companies Unite to Develop Hepatitis C and Hepatitis B Vaccines
October 13, 2011
Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
Data published in Molecular Therapy indicates strong vaccine-generated T cell immune responses in monkeys to consensus multi-antigen HCV vaccine
BLUE BELL, Pa., Oct. 10, 2011 /PRNewswire via COMTEX/ — Inovio Pharmaceuticals, Inc. INO +1.66% , a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc. (kse:011000), to co-develop Inovio’s SynCon® therapeutic vaccines for hepatitis B and C infections.
Under the terms of the agreement, VGX International will receive marketing rights for these vaccines in Asia, excluding Japan, and in return will fully fund IND-enabling and initial phase I and II clinical studies. Inovio will receive payments based on the achievement of clinical milestones and royalties based on sales in the licensed territories and retains all commercial rights in all other territories.
The first product to enter clinical testing will be a synthetic multi-antigen hepatitis C virus (HCV) vaccine covering genotypes 1a and 1b and targeting the antigens NS3/4A, which includes HCV nonstructural proteins 3 (NS3) and 4A (NS4A), as well as NS4B and NS5A proteins.
Continue reading this entire article:
Developmental Hep C Drug Shows Antiviral Potency
Hep C Trial Arm Added Due to Favorable PSI-7977 Data